Use of Cabozantinib in addition to chemotherapy as a viable second line treatment option in Relapsed Refractory Malignant Osteogenic Sarcomas
Year: 2025
Type: article
Abstract: Introduction: Osteosarcoma (OS) and Ewing Sarcoma (ES) are the most common primary bone sarcomas in children.There is no standardized second line treatment for refractory/relapsed (r/r) OS and ES.Targeting aberrant angiogenesis and MET signaling have shown efficacy in research models.Cabozantinib is an oral multiple kinase inhibitor which targets vascular endothelial growth factor receptor 2, c-MET and RET.
Source: OncoDaily Medical Journal
Authors: Dale Jude Montes, Maharshi Trivedi, Helie Raval, Himangi Tak, Chinmay Doctor, Harsha Panchal
Institution: Gujarat Cancer & Research Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4409433420